SCHEMBL11213534

SCHEMBL11213534

CCNCCCCCCCC(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.55
CYP1A2 P05177 1/20 0.55
KDM1A O60341 5/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
GLA P06280 1/20 0.50
TSHR P16473 2/20 0.48
LMNA P02545 1/20 0.42
SAT1 P21673 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HRH4 Q9H3N8 2/20 0.35
HRH3 Q9Y5N1 2/20 0.35
ADH1B P00325 1/20 0.34
ADH1C P00326 1/20 0.34
ADH1A P07327 1/20 0.34
ADH4 P08319 1/20 0.34
ADH7 P40394 1/20 0.34
TP53 P04637 1/20 0.33
KDM4C Q9H3R0 2/20 0.32
KDM4A O75164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26052132 1.00 CYP2C19 (0.55) CYP2C19CYP1A2KDM1AMEN1KMT2A
SCHEMBL15563084 1.00 CYP2C19 (0.55) CYP2C19CYP1A2KDM1AMEN1KMT2A
SCHEMBL17780060 1.00 CYP2C19 (0.55) CYP2C19CYP1A2KDM1AMEN1KMT2A
SCHEMBL11477230 1.00 CYP2C19 (0.55) CYP2C19CYP1A2KDM1AMEN1KMT2A
SCHEMBL10712359 1.00 CYP2C19 (0.55) CYP2C19CYP1A2KDM1AMEN1KMT2A
SCHEMBL10585603 1.00 CYP2C19 (0.55) CYP2C19CYP1A2KDM1AMEN1KMT2A
SCHEMBL11205448 1.00 CYP2C19 (0.55) CYP2C19CYP1A2KDM1AMEN1KMT2A
Hydrochloric Acid SCHEMBL2112301 0.98 CYP2C19 (0.52) CYP2C19CYP1A2KDM1AMEN1KMT2A
SCHEMBL441049 0.97 CYP2C19 (0.57) CYP2C19CYP1A2KDM1AMEN1KMT2A
SCHEMBL20841975 0.91 LMNA (0.58) CYP2C19CYP1A2KDM1AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024105197-A1 SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT VINCERX PHARMA GMBH (DE) 2024-05-23 WO disclosed
WO-2023220425-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 US disclosed
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 US disclosed
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed
EP-3199610-B1 FUEL ADDITIVES AND FUELS CONTAINING THE ADDITIVES AFTON CHEMICAL CORP (US) 2021-05-26 EP disclosed
WO-2020264490-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed
EP-3199610-A1 FUEL ADDITIVES AND FUELS CONTAINING THE ADDITIVES Afton Chemical Corporation (US) 2017-08-02 EP disclosed
US-9353326-B1 Synergistic fuel additives and fuels containing the additives AFTON CHEMICAL CORPORATION (US) 2016-05-31 US disclosed
EP-0031924-B1 USE OF ALCANOL-AMINE SALTS OF CYCLIC AMIDOCARBOXYLIC ACIDS AS CORROSION INHIBITORS IN AQUEOUS SYSTEMS BASF Aktiengesellschaft (DE) 1983-05-18 EP disclosed
EP-0031924-A1 Use of alcanol-amine salts of cyclic amidocarboxylic acids as corrosion inhibitors in aqueous systems BASF Aktiengesellschaft (DE) 1981-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CYP2C19 3990/4885CYP1A2 3570/4885KDM1A 160/4885
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CYP2C19 3990/4885CYP1A2 3570/4885KDM1A 160/4885
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CYP2C19 3990/4885CYP1A2 3570/4885KDM1A 160/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CYP2C19 3990/4885CYP1A2 3570/4885KDM1A 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.